Russian Journal of OncologyRussian Journal of OncologyРоссийский онкологический журнал1028-99842412-9119Eco-Vector4010510.17816/onco40105ArticlesСтатьиResearch ArticleRelationship between clinical and morphological parameters and survival in non-small cell lung cancer with protein expression and gene HER2-neu amplificationВзаимосвязь клинико-морфологических параметров и выживаемости при немелкоклеточном раке легкого с экспрессией белка и амплификацией гена HER2-neuKobyakovDmitriy S.КобяковДмитрий Сергеевич

MD, PhD

канд. мед. наук, зав. патологоанатомическим отделением

dskob@yandex.ruAvdalyanA. MАвдалянА. М

Altai branch

Алтайский филиал

LazarevA. FЛазаревА. Ф

Altai branch

Алтайский филиал

LushnikovaE. LЛушниковаЕ. ЛNepomnyaschikhL. MНепомнящихЛ. МKogalymskaya City HospitalБюджетное учреждение «Когалымская городская больница»N.N. Blokhin Russian Cancer Research Center under the Russian Academy of Medical SciencesФГБУ «Российский онкологический научный центр им. Н.Н. Блохина»Research Institute of Regional Pathology and Pathomorphology Siberian Department RAMSФГБУ «Научно-исследовательский институт региональной патологии и патоморфологии» СО РАМН15102014195VOL 19, NO5 (2014)ТОМ 19, №5 (2014)313622072020Copyright ©; 2014, Eco-VectorCopyright ©; 2014, ООО "Эко-Вектор"2014Eco-VectorООО "Эко-Вектор"https://rjonco.com/1028-9984/article/view/40105

Purpose. Study of the content ofprotein HER2 and gene HER2 , CEP17 in conjunction with clinical and morphological parameters and survival in non-small cell lung cancer. Material and methods. Investigated 218 surgery samples of non-small cell lung cancer. HER2 protein was determined by immunohistochemistry (clone 4B5, «Ventana») andgene HER2, CEP17 by hybridization in situ (SISH, «Ventana»). Results. Found relationship between the clinical and morphological parameters on the TNM system with protein HER2 status and CEP17 (for value N), protein HER2 status and gene HER2 amplification (for tumor histogenesis). Survival ofpatients with protein HER2 negative status better than positive status. Found better survival in the absence of gene HER2 amplification and increase CEP17 or gene HER2 amplification in conjunction with increase CEP17, the worse survival - gene HER2 amplification or increase CEP17. In univariate regression analysis protein HER2 status had an impact on survival. Multivariate regression analysis showed no relationship protein HER2 status and gene HER2, CEP17 with patient survival. Conclusion. The content ofprotein HER2 and gene HER2, CEP17 correlated with clinical and morphological parameters and survival of non-small cell lung cancer patients.

Цель - исследовать содержание белка HER2 и гена HER2, CEP17 во взаимосвязи с клинико-морфологическими параметрами и выживаемостью при немелкоклеточном раке легкого. Материал и методы. Исследованы 218 операционных материалов немелкоклеточного рака легкого. Определяли белок HER2 методом иммуногистохимии (клон 4В5, Ventana) и ген HER2, CEP17 методом гибридизации in situ (SISH, Ventana). Результаты. Найдена связь клинико-морфологических параметров по системе TNM с содержанием белка HER2 и состоянием CEP17 (для показателя N), содержанием белка HER2 и амплификацией гена HER2 (для гистогенеза опухоли). Выживаемость больных с HERl-отрицательным статусом лучше по сравнению с HER2-положительным статусом. Найдена высокая выживаемость больных при отсутствии амплификации гена HER2 и увеличения CEP17 или при наличии амплификации гена HER2 совместно с увеличением CEP17, низкая - при наличии амплификации гена HER2 или увеличения CEP17. При однофакторном регрессионном анализе HER2-сmаmус опухоли имел влияние на выживаемость больных. Многофакторный регрессионный анализ не выявил взаимосвязи содержания белка HER2 и состояния гена HER2, CEP17 с выживаемостью больных. Заключение. Содержание белка HER2 и гена HER2, CEP17 имеет связь с клинико-морфологическими параметрами и выживаемостью больных немелкоклеточным раком легкого.

HER2immunohistochemistryhybridization in situnon-small cell lung cancerиммуногистохимиягибридизации in situнемелкоклеточный рак легкогоReinmuth N., Brandt B., Kunze W.P., Junker K., Thomas M., Achatzy R. et al. Ploidy, expression of erbB1, erbB2, p53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur. Respir. J. 2000; 16: 991-6.Hofmann M., Stoss O., Shi D., Buttner R., van de Vijver M., Kim W. et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52: 797-805.Schraml P., Kononen J., Bubendorf L., Moch H., Bissig H., Nocito A. et al. Tissue microarrays for gene amplification surveys in many different tumor types. Clin. Cancer. Res. 1999; 5: 1966-75.Au N.H., Cheang M., Huntsman D.G., Yorida E., Coldman A., Elliott W.M. et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J. Pathol. 2004; 204: 101-9.Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I. , Bartolini S., Ceresoli G.L. et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. 2005; 23: 5007-18.Cox G., Vyberg M., Melgaard B., Askaa J., Oster A., O’Byme K.J. Herceptest: HER2 expression and gene amplification in nonsmall cell lung cancer. Int. J. Cancer. 2001; 92: 480-3.Grob T.J., Kannengiesser I., Tsourlakis M.C., Atanackovic D. , Koenig A.M., Vashist Y.K. et al. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod. Pathol. 2012; 25: 1566-73.Hirashima N., Takahashi W., Yoshii S., Yamane T., Ooi A. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod. Pathol. 2001; 14: 556-62.Hirsch F.R., Varella-Garcia M., Franklin W.A., Veve R., Chen L., Helfrich B. et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer. 2002; 86: 1449-56.Hsieh C.C., Chow K.C., Fahn H.J., Tsai C.M., Li W.Y., Huang M.H. et al. Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Ann. Thorac. Surg. 1998; 66: 1159-64.Nakamura H., Saji H., Ogata A., Hosaka M., Hagiwara M., Kawasaki N. et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int. J. Cancer. 2003; 103: 61-6.Pelosi G., Del Curto B., Dell’Orto P., Pasini F., Veronesi G., Spaggiari L. et al. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int. J. Cancer. 2005; 113: 101-8.Tan D., Deeb G., Wang J., Slocum H.K., Winston J., Wiseman S. et al. HER-2/neu protein expression and gene alteration in stage I-IIIA nonsmall-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn. Mol. Pathol. 2003; 12: 201-11.Liu L., Shao X., Gao W., Bai J., Wang R., Huang P. et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J. Thorac. Oncol. 2010; 5: 1922-32.Sobin L., Gospodarowicz M., Wittekind C. (Eds.): TNM Classification of Malignant Tumours. 7th Ed. Oxford: Wiley-Blackwell, 2009: 138-46.Wang S., Hossein Saboorian M., Frenkel E.P., Haley B.B., Siddiqui M.T., Gokaslan S. et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod. Pathol. 2002; 15: 137-45.Panagiotou I., Georgiannos S.N., Tsiambas E., Karameris A., Konstantinou M., Lazaris A.C. et al. Impact of HER2 and PTEN simultaneous deregulation in non-small cell lung carcinoma: correlation with biological behavior. Asian Pac. J. Cancer. Prev. 2012; 13: 6311-8.Marchio C., Lambros M.B., Gugliotta P., Di Cantogno L.V., Botta C., Pasini B. et al. Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 2009; 219: 16-24.Ma J., Gao M., Lu Y., Feng X., Zhang J., Lin D. et al. Gain of 1q25-32, 12q23-24.3, and 17q12-22 facilitates tumorigenesis and progression of human squamous cell lung cancer. J. Pathol. 2006; 210: 205-13.Onchi H., Hirose K., Yamaguchi A., Noriki S., Fukuda M. Prognostic value of numerical aberrations of chromosome 17 in differentiated gastric cancer: evaluation by multivariate regression analysis. Oncol. Rep. 2000; 7: 1317-22.Yoon H.H., Shi Q., Sukov W.R., Lewis M.A., Sattler C.A., Wiktor A.E. et al. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. J. Clin. Oncol. 2012; 30: 3932-8.Vanden Bempt I., Van Loo P., Drijkoningen M., Neven P., Smeets A, Christiaens M.R. et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J. Clin. Oncol. 2008; 26: 4869-74.